22024 Nexgener Co., Ltd. is a service company that supports the entire drug development cycle based on new drug development and drug delivery technology based on an unrivaled technology platform.
As a company specializing in new drug development, we develop and service new drugs based on Drug Drug Conjugation, Antibody Drug Conjugation, CAR-T, CAR-NK, killed vaccine, and ASO technologies.
In addition, as a company specializing in DDS formulation development, we design and service DDS formulations such as LNP and Liposome based on lipoprotein synthesis, oligonucleic acid synthesis, and antibody design and production technology.
He served as a professor at the College of Pharmacy and dean of the Graduate School of Pharmaceutical Clinical Sciences at Ajou University, and at the Advanced Medical Bio Research Institute.
A close relationship centered on CEO Kim Soo-dong, who serves as the chairman of the Advanced Medical Products Licensing Verification Research Institute.
Through the industry-university-research network, we provide information on bio and synthetic raw materials drugs, including (non-)clinical translational research.
We support preparation of DMF, CMC, licensing documents and production of (non-)clinical samples based on BGMP.
Comments